New Delhi, Nov 19 (PTI) Alkem Laboratories on Thursday said it has received a warning letter from the US Food and Drug Administration (USFDA) for its manufacturing facility at Amaliya, Daman.
In a regulatory filing, the company said the warning letter, dated November 18, was issued after a USFDA inspection of the facility from April 20 to May 1, 2026.
The US health regulator classified the Daman facility's inspection status as Official Action Indicated (OAI), citing regulatory violations.
According to the filing, the warning letter pertains to observations made by the USFDA during the inspection and requires the company to implement appropriate corrective and preventive actions to address the observations and prevent recurrence.
Alkem Laboratories said it will respond to the USFDA within the stipulated timeline.
The company added that it continues to manufacture and supply approved products from the facility to the US market, and there is no material impact on its current operations, financial or other activities.